Pharma Backing of Advocacy Groups: A Call for Transparency
From HealthNewsReview.org: In light of the opioid crisis, lawmakers are growing increasingly concerned about financial conflicts of interest in patient advocacy groups. Ontario has enacted...
Researchers Push for Transparency of Mental Health Outcome Data
A new analysis of UK mental health data suggests the way organizations deliver mental health services can alter patient outcomes.
Scientists Call for Increased Transparency in Research
Scientists at the Yale Collaboration for Research Integrity and Transparency (CRIT) published a new policy paper this month criticizing the current state of biomedical research and calling for improved transparency in research methods.
Payment Disclosure Bill is a Good First Step, but More is...
From The Globe and Mail: Ontario's newly proposed physician-payment disclosure law is an important first step in the direction of improved health care and increased...
Ontario Bill Will Reveal Drug Company Payments to Doctors
From the Toronto Star: The province of Ontario has introduced a new transparency bill that will require pharmaceutical and medical device companies to disclose payments they make...
Biotech Exploits a Loophole in a Federal Transparency Law
From STAT: A small biotech company, AveXis, recently offered a $3,000 honorarium along with paid airfare and lodging to several experts to attend a so-called...
Two Thirds of Patients See Physicians Who Receive Payments From Pharma
Study finds more patients are visiting physicians who have ties to industry than previously thought.
Many Patient Advocacy Organizations Are Funded By Industry
New research investigates the financial conflicts of interest (FCOI) of patient advocacy organizations (PAOs) in the United States.
Interview: Researchers Deconstruct Ghostwritten Industry Trial for Antidepressant
Researchers, Jon Jureidini, Jay Amsterdam and Leemon McHenry, have taken a closer look at the data from a randomized control trial of citalopram (Celexa) that was ghostwritten and then used by the manufacturers to support claims of the drug’s efficacy and safety in the treatment of child and adolescent depression. To get the background on this story, we connected with Dr. Leemon McHenry, an investigator in this study and a lecturer in philosophy at California State University, Northridge.
GlaxoSmithKline Accused of Hiding Paroxetine Results
The UK Times reports that pharmaceutical companies are actively lobbying to limit the release of clinical trial data to the public. Rather than limiting results and data to medical journals, new transparency initiatives are pushing for making the information publically available. The push for transparency comes in the wake of the reanalysis of the Study 329 data on paroxetine (marketed as Seroxat and Paxil), which found that the industry study had misconstrued its results.